Cargando…
Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers
In Hungary, the cost of lenalidomide-based therapy is covered only for relapsed multiple myeloma (MM) patients, therefore lenalidomide is typically used in the second-line either as part of a triplet with proteasome inhibitors or as a doublet. Lenalidomide-dexamethasone is a standard treatment appro...
Autores principales: | Varga, Gergely, Dávid Tóth, András, Réka Szita, Virág, Csukly, Zoltán, Hardi, Apor, Gaál-Weisinger, Júlia, Nagy, Zsolt, Altai, Elvira, Rencsik, Annamária, Plander, Márk, Szendrei, Tamás, Kórád, Krisztina, Radványi, Gáspár, Rottek, János, Deák, Beáta, Szaleczky, Erika, Schneider, Tamás, Kohl, Zoltán, Kosztolányi, Szabolcs, Alizadeh, Hussain, Lengyel, Zsuzsanna, Modok, Szabolcs, Borbényi, Zita, Lovas, Szilvia, Váróczy, László, Illés, Árpád, Rajnics, Péter, Masszi, Tamás, Mikala, Gábor |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262242/ https://www.ncbi.nlm.nih.gov/pubmed/34257583 http://dx.doi.org/10.3389/pore.2021.613264 |
Ejemplares similares
-
Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers
por: Szita, Virág Réka, et al.
Publicado: (2022) -
Real World Efficacy and Safety Results of Ixazomib Lenalidomide and Dexamethasone Combination in Relapsed/Refractory Multiple Myeloma: Data Collected from the Hungarian Ixazomib Named Patient Program
por: Varga, Gergely, et al.
Publicado: (2019) -
Pomalidomide Treatment in Relapsed/Refractory Multiple Myeloma Patients—Real-World Data From Hungary
por: Lovas, Szilvia, et al.
Publicado: (2022) -
Revealing a Phenotypical Appearance of Ibrutinib Resistance in Patients With Chronic Lymphocytic Leukaemia by Flow Cytometry
por: Takács, Ferenc, et al.
Publicado: (2022) -
PB1909: LOW-BURDEN TP53 MUTATIONS REPRESENT FREQUENT GENETIC EVENTS IN CLL WITH AN INCREASED RISK FOR TREATMENT INITIATION
por: László, Tamás, et al.
Publicado: (2023)